Omar Hasan Ali: Influence Statistics

Omar Hasan Ali

Omar Hasan Ali

Institute of Immunobiology, Kantonsspital St. Gallen, Rorschacher Strasse 95, 9007, St. Gallen, Switzerland | Department of Dermatology, University Hospital Zurich, ...

Omar Hasan Ali: Expert Impact

Concepts for which Omar Hasan Ali has direct influence: Checkpoint inhibitors , Skin reactions , Therapy response , Cell lung , Melanoma patients , Iciinduced hepatitis , Small cell .

Omar Hasan Ali: KOL impact

Concepts related to the work of other authors for which for which Omar Hasan Ali has influence: Immune checkpoint inhibitors , Cell lung , Patients iraes , Sensitive skin , Clinical benefit , Metastatic melanoma , Checkpoint blockade .

KOL Resume for Omar Hasan Ali

Year
2021

Institute of Immunobiology, Kantonsspital St. Gallen, Rorschacher Strasse 95, 9007, St. Gallen, Switzerland

2020

Institute for Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland.

2019

Institute of Immunobiology, Kantonsspital St.Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland

2018

Institute of Immunobiology, Kantonsspital St. Gallen, St. Gallen, Switzerland,

Dermatologie, Kantonsspital, St. Gallen, Switzerland

2017

Institute of Immunobiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

2016

Department of Dermatology and Allergology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland; Institute of Immunobiolology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

Prominent publications by Omar Hasan Ali

KOL-Index: 8185 . Prognosis of metastatic melanoma improved with the development of checkpoint inhibitors. The role of tumor infiltrating lymphocytes (TILs) in lymph node metastases of stage III melanoma remains unclear. We retrospectively characterized TILs in primary melanomas and matched lymph node metastases (stage III melanoma) of patients treated with the checkpoint inhibitor ipilimumab. Tumor ...
Known for Lymph Node | Tumor Infiltrating | Melanoma Patients | Response Ipilimumab
KOL-Index: 5936 . BACKGROUND: Anti-programmed cell death protein 1 (PD1)/programmed death-ligand 1(PD-L1) therapy frequently entails immune-related adverse events (irAEs), and biomarkers to predict irAEs are lacking. Although checkpoint inhibitors have been found to reinvigorate T cells, the relevance of autoantibodies remains elusive. OBJECTIVE: Our aim was to explore whether IgG autoantibodies directed ...
Known for Checkpoint Inhibitors | Cell Lung | Skin Iraes | Death 1
KOL-Index: 5438 . BackgroundLong-term survival of stage IV melanoma patients has improved significantly with the development of immune checkpoint inhibitors (CIs). Reliable biomarkers to predict response and clinical outcome are needed.MethodsWe investigated the role of melanoma-associated antibodies as predictive markers for CI therapy in two independent cohorts. In cohort 1, a prospective study, we ...
Known for Melanoma Patients | Antibodies Monoclonal | Response Survival | Reliable Biomarkers
KOL-Index: 5038 . Immune checkpoint inhibitors have led to considerable therapy improvement in cancer patients. Autoimmune side effects including skin reactions are frequently observed. In melanoma, those include rash and vitiligo and were shown to be associated with a prolonged overall survival. Little is known about skin reactions in non-small cell lung cancer (NSCLC) patients during immunotherapy. Here, ...
Known for Skin Reactions | Patients Nsclc | Cell Lung | Tumor Responses
KOL-Index: 2306 . Pruritus is associated with various skin diseases, dry skin, and with it an impaired skin barrier function. The study objective was to investigate short-term and long-term effects of two emollients on symptoms and skin barrier functions in xerotic eczema. Randomized, double-blind, study enrolling females/males, with bilateral itching. Two emollients, containing lactic acid and refined ...
Known for Itching Severity | Dry Skin | Publication Administration | Eczema Emollients
KOL-Index: 2258 . PURPOSE: Characterize ocular adverse events (oAEs) caused by immune checkpoint inhibitors (ICIs). METHODS: Retrospective analysis of 41,674 cancer patients in the FDA Adverse Event Reporting System (FAERS) pharmacovigilance database receiving anti-PD-1/PD-L1, anti-CTLA-4, or anti-PD-1+ anti-CTLA-4 combination. Reporting odds ratio (ROR) was used to approximate oAE rate across regimens and ...
Known for Immune Checkpoint Inhibitors | Lung Cancer | Adverse Event | Pd1 L1
KOL-Index: 184 . Background: Prognosis of metastatic non-small cell lung cancer significantly improved with the availability of checkpoint inhibitors (anti-PD-1/PD-L1). Unfortunately, reliable biomarkers to predict treatment benefit are lacking. Patients and methods: We prospectively collected clinical and laboratory data of 56 non-small cell lung cancer patients treated with a checkpoint inhibitor. The ...
Known for Checkpoint Inhibitors

Key People For Checkpoint Inhibitors

Top KOLs in the world
#1
Jedd D Wolchok
advanced melanoma tumor immunity nivolumab ipilimumab
#2
Frank Stephen Hodi
advanced melanoma brain metastases nivolumab ipilimumab
#3
Julie Renee Brahmer
lung cancer small cell advanced nsclc
#4
Caroline Robert
advanced melanoma braf v600 advisory consultancy
#5
Dirk Schadendorf
melanoma patients advisory consultancy braf v600
#6
Drew M Pardoll
tumor cells prostate cancer inbred balb mice

Institute of Immunobiology, Kantonsspital St. Gallen, Rorschacher Strasse 95, 9007, St. Gallen, Switzerland | Department of Dermatology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland | Institute for Immunobiology, Kantonsspit